These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11422025)

  • 21. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients.
    Merry C; Barry MG; Mulcahy F; Ryan M; Heavey J; Tjia JF; Gibbons SE; Breckenridge AM; Back DJ
    AIDS; 1997 Mar; 11(4):F29-33. PubMed ID: 9084785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration.
    Buss N; Snell P; Bock J; Hsu A; Jorga K
    Br J Clin Pharmacol; 2001 Sep; 52(3):255-64. PubMed ID: 11560557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.
    Dickinson L; Boffito M; Back DJ; Khoo SH; Pozniak AL; Mugyenyi P; Merry C; Autar RS; Burger DM; Aarons LJ
    J Antimicrob Chemother; 2008 Dec; 62(6):1344-55. PubMed ID: 18824460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
    von Hentig N; Müller A; Rottmann C; Wolf T; Lutz T; Klauke S; Kurowski M; Oertel B; Dauer B; Harder S; Staszewski S
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1431-9. PubMed ID: 17296738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir.
    Gisolf EH; van Heeswijk RP; Hoetelmans RW; Danner SA
    AIDS; 2000 May; 14(7):801-5. PubMed ID: 10839587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.
    Cardiello PG; Monhaphol T; Mahanontharit A; van Heeswijk RP; Burger D; Hill A; Ruxrungtham K; Lange JM; Cooper DA; Phanuphak P
    J Acquir Immune Defic Syndr; 2003 Apr; 32(4):375-9. PubMed ID: 12640194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.
    Kilby JM; Sfakianos G; Gizzi N; Siemon-Hryczyk P; Ehrensing E; Oo C; Buss N; Saag MS
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2672-8. PubMed ID: 10991842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers.
    Sekar VJ; Lefebvre E; Mariën K; De Pauw M; Vangeneugden T; Hoetelmans RM
    Ther Drug Monit; 2007 Dec; 29(6):795-801. PubMed ID: 18043478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Saquinavir: a review of its use in boosted regimens for treating HIV infection.
    Plosker GL; Scott LJ
    Drugs; 2003; 63(12):1299-324. PubMed ID: 12790697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats.
    Shibata N; Kageyama M; Kishida T; Kimura K; Yoshikawa Y; Kuwahara T; Toh J; Shirasaka T; Takada K
    Biopharm Drug Dispos; 2003 Nov; 24(8):335-44. PubMed ID: 14595702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers.
    Bittner B; Riek M; Holmes B; Grange S
    Antivir Ther; 2005; 10(7):803-10. PubMed ID: 16312177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients.
    Autar RS; Boffito M; Hassink E; Wit FW; Ananworanich J; Siangphoe U; Pozniak A; Cooper DA; Phanuphak P; Lange JM; Ruxrungtham K; Burger DM
    J Antimicrob Chemother; 2005 Nov; 56(5):908-13. PubMed ID: 16204340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.
    Autar RS; Ananworanich J; Apateerapong W; Sankote J; Hill A; Hirschel B; Cooper D; Lange J; Phanuphak P; Ruxrungtham K; Burger D
    J Antimicrob Chemother; 2004 Oct; 54(4):785-90. PubMed ID: 15329366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.
    Stephan C; von Hentig N; Kourbeti I; Dauer B; Mösch M; Lutz T; Klauke S; Harder S; Kurowski M; Staszewski S
    AIDS; 2004 Feb; 18(3):503-8. PubMed ID: 15090803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No significant influence of saquinavir hard-gel capsule administration on pharmacokinetics of lopinavir in combination with ritonavir: a population approach.
    Dailly E; Gagnieu MC; Allavena C; Raffi F; Jolliet P
    Ther Drug Monit; 2005 Dec; 27(6):782-4. PubMed ID: 16306855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects.
    Singh K; Dickinson L; Chaikan A; Back D; Fletcher C; Pozniak A; Moyle G; Nelson M; Gazzard B; Herath D; Boffito M
    Clin Pharmacol Ther; 2008 Jun; 83(6):867-72. PubMed ID: 17898705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens.
    Pellegrin I; Breilh D; Birac V; Deneyrolles M; Mercié P; Trylesinski A; Neau D; Saux MC; Fleury HJ; Pellegrin JL
    Ther Drug Monit; 2001 Aug; 23(4):332-40. PubMed ID: 11477313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.
    Marin-Niebla A; Lopez-Cortes LF; Ruiz-Valderas R; Viciana P; Mata R; Gutierrez A; Pascual R; Rodriguez M
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2035-42. PubMed ID: 17371813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.
    Jamois C; Smith P; Morrison R; Riek M; Patel A; Schmitt C; Morcos PN; Zhang X
    Addict Biol; 2009 Jul; 14(3):321-7. PubMed ID: 19523046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study).
    Ribera E; Azuaje C; Lopez RM; Domingo P; Soriano A; Pou L; Sánchez P; Mallolas J; Sambea MA; Falco V; Ocaña I; Lopez-Colomes JL; Gatell JM; Pahissa A
    J Acquir Immune Defic Syndr; 2005 Nov; 40(3):317-23. PubMed ID: 16249706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.